# US Needle Biopsy Market

> US Needle Biopsy Market Research Report: Size, Share, Trend Analysis By Types (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy), By Applications (Oncology, Cardiology, Gastroenterology, Pulmonology), By Guidance Technique (Ultrasound Guided, CT Guided, Mammography Guided) and By End Use (Hospitals, Diagnostic Laboratories, Research Institutions) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.91%
- **2024:** $ 575.75 Million
- **2025:** $ 604.02 Million
- **2035:** $ 975.48 Million
- **Key Players:** Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Cook Medical LLC (US), Cardinal Health, Inc. (US), Terumo Corporation (JP), Fujifilm Holdings Corporation (JP), Olympus Corporation (JP)

**Report ID:** MRFR/MED/17917-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-needle-biopsy-market-19464

---

## Market Summary

## **US Needle Biopsy Market Overview**

As per MRFR analysis, the US Needle Biopsy Market Size was estimated at 470.4 (USD Million) in 2023. The US Needle Biopsy Market Industry is expected to grow from 491.4 (USD Million) in 2024 to 885.65 (USD Million) by 2035. The US Needle Biopsy Market CAGR (growth rate) is expected to be around 5.501% during the forecast period (2025 - 2035).

### **Key US Needle Biopsy Market Trends Highlighted**

The US Needle Biopsy Market is seeing significant trends driven by advancements in technology and the increasing prevalence of cancer. The introduction of minimally invasive biopsy techniques is one of the key market drivers, as these methods significantly reduce patient recovery time and associated risks, making them more favorable for both healthcare providers and patients. Moreover, the growth in the geriatric population in the US is increasing the demand for diagnostic procedures like needle biopsies, as older individuals are more susceptible to cancer and other chronic diseases.

Opportunities in the US market are notable with the ongoing development of innovative biopsy devices and techniques that enhance precision and accuracy. The rise of image-guided biopsies, including ultrasound and CT-guided procedures, is particularly significant as these methods improve diagnostic confidence and streamline clinical workflows. Also, there is potential growth in telemedicine, which allows for remote consultations and follow-ups related to biopsy procedures, improving patient accessibility and satisfaction.

Recent trends indicate a shift toward personalized medicine, where needle biopsy plays a crucial role in tumor profiling and treatment decision-making. As molecular diagnostics gain traction, the capabilities of needle biopsies are expanding, enabling oncologists to tailor therapies based on the specific characteristics of tumors. Furthermore, the integration of artificial intelligence in pathology to analyze biopsy samples is on the rise, enhancing diagnostic accuracy and operational efficiency. Overall, the US Needle Biopsy Market is on an upward trajectory supported by technological innovations and evolving healthcare demands.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Needle Biopsy Market Drivers**

#### **Increasing Incidence of Cancer**

The rising incidence of cancer in the United States is a significant driver for the US Needle Biopsy Market Industry. According to the American Cancer Society, it is projected that there will be approximately 1.9 million new cancer cases diagnosed in the year 2021 alone, with breast, lung, prostate, and colorectal cancers accounting for a large portion of these cases. This alarming statistic highlights the urgent need for diagnostic procedures like needle biopsy, which is essential for accurate cancer diagnosis and staging.

Furthermore, the National Cancer Institute indicates that more advanced needle biopsy techniques are becoming increasingly important due to their ability to provide less invasive options for obtaining tissue samples. As the prevalence of cancer continues to rise, this trend is expected to drive growth within the US Needle Biopsy Market, enhancing the demand for various types of needle biopsy devices and services, facilitating early detection, and ultimately improving patient outcomes.

#### **Advancements in Needle Biopsy Technologies**

Technological advancements are another crucial driver for the US Needle Biopsy Market Industry. The development of innovative devices such as automated biopsy systems, imaging-guided biopsy techniques, and advancements in needle design have significantly improved the accuracy and efficiency of needle biopsies. For example, multiple organizations, including the American Society of Clinical Oncology, have endorsed the use of Ultrasound and CT-guided biopsy techniques due to their lower complication rates and higher diagnostic accuracy.

The ability to streamline procedures and reduce patient discomfort not only enhances the overall biopsy experience but also increases the adoption of needle biopsy processes in outpatient settings. With continuous Research and Development efforts from major players in the medical device market, such as Boston Scientific and Medtronic, the industry is likely to see ongoing innovation, further driving market growth over the coming years.

#### **Rising Awareness About Early Diagnosis**

Increasing awareness of the importance of early diagnosis among patients and healthcare providers significantly elevates the demand for needle biopsy procedures in the US Needle Biopsy Market Industry. Organizations such as the Centers for Disease Control and Prevention (CDC) have been actively promoting cancer screening and early detection initiatives, resulting in more individuals seeking diagnostic procedures when experiencing potential symptoms.

With government campaigns and educational programs urging people to be proactive about their health, the number of patients seeking needle biopsies is expected to rise. A growing patient population recognizing the essential role of timely interventions and the importance of following recommended screening guidelines will consequently enhance the adoption of needle biopsy procedures, fostering market growth in the United States.

### **US Needle Biopsy Market Segment Insights**

#### **Needle Biopsy Market Type Insights**

The US Needle Biopsy Market encompasses various types, each serving distinct applications in the medical field. A prominent type is Fine Needle Aspiration Biopsy (FNAB), which is widely adopted due to its minimally invasive nature. This method enables the extraction of cellular material from lesions and masses for cytological examination, making it an essential tool in oncology for rapid diagnosis and treatment planning. Its efficiency and relatively low complication rate contribute to its significant presence in the market, catering to patients who require quick and less painful procedures.

Core Needle Biopsy serves as another vital component of the US Needle Biopsy Market. It typically involves the use of a larger needle compared to FNAB and allows for the extraction of a tissue sample, providing more substantial information for histopathological analysis. This type is particularly significant when deeper or larger samples are necessary, which is often the case in breast or prostate biopsies. As the healthcare industry increasingly leans towards precise and effective diagnostic techniques, Core Needle Biopsy stands out due to its accuracy and the ability to provide comprehensive information on tissue architecture.

Vacuum-Assisted Biopsy (VAB) is also gaining prominence in the US Needle Biopsy Market. This technique utilizes a vacuum mechanism to remove multiple tissue samples in a single insertion, often leading to fewer complications and less patient discomfort. VAB is especially beneficial for breast biopsies, allowing for a more extensive examination of suspicious areas without the need for multiple needle insertions. As advances in technology continue to enhance procedural efficiency, the importance of Vacuum-Assisted Biopsy is expected to rise.

Trends in the US healthcare sector are leaning towards minimally invasive procedures, thereby driving the growth of these various types of needle biopsies. An increased focus on early detection and screening, especially for conditions like cancer, is propelling the demand for these procedures. Furthermore, the rise in awareness among patients and healthcare professionals regarding the benefits of needle biopsy techniques is significantly influencing market dynamics. Overall, the segmentation within the US Needle Biopsy Market reflects a diverse landscape where innovations in technique and technology profoundly impact patient outcomes and healthcare practices.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Needle Biopsy Market Application Insights**

The Application segment of the US Needle Biopsy Market plays a crucial role in facilitating precise diagnostic and therapeutic procedures, covering vital areas such as Oncology, Cardiology, Gastroenterology, and Pulmonology. Oncology holds a particularly significant position within this market, driven by the increasing incidence of cancer and the demand for early detection methods to improve patient survival rates. Cardiology is becoming increasingly relevant as needle biopsies enable minimally invasive procedures for diagnosing heart conditions.

Gastroenterology benefits from needle biopsies for assessing liver diseases and gastrointestinal tract disorders, significantly enhancing patient management. In Pulmonology, the importance of needle biopsy procedures has surged, especially with the rising prevalence of respiratory disorders, allowing for effective tissue sampling from lung lesions. The market is anticipated to experience growth due to trends focusing on minimally invasive techniques and enhancements in diagnostic accuracy. Additionally, the demand for advanced imaging technologies and the increasing interest in personalized treatment options are further driving the focus within these applications in the US Needle Biopsy Market.

Overall, the segmentation within the application area underpins significant advancements in patient care and treatment strategies across various medical fields.

#### **Needle Biopsy Market Guidance Technique Insights**

The Guidance Technique segment of the US Needle Biopsy Market plays a pivotal role in enhancing diagnostic accuracy and procedural efficiency. This segment includes techniques such as Ultrasound Guided, CT Guided, and Mammography Guided biopsies, each offering unique benefits that cater to different clinical needs. Ultrasound Guided biopsies are widely regarded for their real-time imaging capabilities, allowing for precise needle placement, thereby minimizing patient discomfort and improving specimen quality. CT Guided techniques are particularly valued for their effectiveness in targeting lesions that are not easily accessible, making them crucial in various oncological applications.

Meanwhile, Mammography Guided biopsies are essential for targeting suspicious breast tissue, ensuring that the correct area is sampled for accurate diagnosis. The significance of these techniques within the US Needle Biopsy Market is underscored by the increasing incidence of cancer diagnoses and the growing emphasis on minimally invasive procedures. As technological advancements continue to evolve, the adoption of these guidance techniques is expected to enhance patient outcomes and streamline workflows in healthcare settings. Overall, the focus on precise and efficient biopsy procedures in the US drives innovative solutions and expands the capabilities of healthcare professionals in diagnostic medicine.

#### **Needle Biopsy Market End Use Insights**

The US Needle Biopsy Market, particularly within the End Use segment, showcases a robust landscape consisting of various vital components that are integral to healthcare delivery. Hospitals play a crucial role as primary providers of needle biopsy procedures, ensuring that patients receive timely diagnostics for conditions such as cancer. The emphasis on rapid and accurate diagnosis has bolstered the demand for such procedures, making hospitals a dominant force in this segment. Diagnostic Laboratories also significantly contribute to this market, serving as specialized centers that enhance the precision and reliability of biopsy analyses, which is critical for effective patient treatment plans.

Additionally, Research Institutions are essential as they drive innovation and development within the needle biopsy field, focusing on enhancing techniques and technologies that improve accuracy and patient outcomes. Overall, the interplay between these three key areas underscores the importance of the End Use segment in the US Needle Biopsy Market, facilitating advancements in medical technology while addressing patient care needs efficiently. The growth in this segment is also supported by the increasing prevalence of chronic diseases and the rising emphasis on early diagnosis.

### **US Needle Biopsy Market Key Players and Competitive Insights**

The US Needle Biopsy Market is a dynamic segment characterized by rapid advancements in medical technology and increasing demand for minimally invasive procedures. This market encompasses a variety of biopsy tools and systems designed for tissue collection, essential for accurate diagnosis in oncology and other medical fields. As the market continues to expand, driven by an aging population and rising incidence rates of diseases requiring biopsy procedures, competition among key players intensifies. Companies are focusing on innovation, product differentiation, and strategic partnerships to enhance their market position.

The competitive landscape reveals a mix of established entities and emerging firms, all striving to capture share in this lucrative market, leading to a robust environment marked by ongoing technological innovations and regulatory advancements.

Devicor Medical Products holds a strong presence in the US Needle Biopsy Market, recognized for its commitment to high-quality biopsy solutions tailored for healthcare providers. The company specializes in advanced device development aimed at improving patient outcomes through precision and efficiency. Devicor Medical Products differentiates itself with its user-friendly devices that facilitate faster procedures and reduce the risk of complications. Its innovative approach, combined with a focus on comprehensive training and support for medical professionals, positions the company favorably within the market.

By continually investing in research and development, Devicor Medical Products strengthens its portfolio, harnessing the latest technologies and positioning itself as a leader in the needle biopsy sector within the United States.

Hologic is another significant player in the US Needle Biopsy Market, renowned for its comprehensive range of diagnostic solutions. The company provides a suite of key products and services including advanced imaging systems and innovative biopsy devices, which cater to various clinical needs in breast health and interventions. Hologic leverages its strong market presence through strategic mergers and acquisitions, enhancing its capabilities and expanding its product offerings. The integration of cutting-edge technology and a commitment to quality allows Hologic to maintain a competitive edge.

Furthermore, the company emphasizes partnerships with medical professionals, ensuring that its product solutions meet the evolving demands of healthcare facilities across the US. With a focus on innovation and high-performance products, Hologic continues to make significant strides in the needle biopsy arena, reinforcing its reputation as a trusted partner in enhancing patient care.

#### **Key Companies in the US Needle Biopsy Market Include**

### **US Needle Biopsy Market Industry Developments**

The US Needle Biopsy Market has been increasingly dynamic in recent months, showcasing significant innovations and developments. In September 2023, Devicor Medical Products announced enhancements to its biopsy platform, improving precision in targeting lesions, which is expected to impact diagnostic accuracy positively. Meanwhile, Hologic expanded its portfolio with new biopsy systems tailored for breast cancer diagnostics, indicating a shift towards advanced technologies aimed at improving patient outcomes. Market demands are also evident with Boston Scientific's new partnerships to integrate advanced imaging techniques into their biopsy devices, thereby enhancing procedural efficiency.

Additionally, there have been notable movements in the corporate landscape, with Medtronic acquiring a niche player in the biopsy market in August 2023, which is aimed at broadening its product offerings. The overall market has seen consistent growth, with 2022 valuations reported at approximately USD 3 billion, and projections suggesting a compound annual growth rate of over 5% through 2028, underlining the potential for innovative biopsy solutions to address rising healthcare needs in the US. As companies like Ethicon and Cook Medical refine their strategies, competitive dynamics within the US Needle Biopsy Market continue to evolve robustly.

### **US Needle Biopsy Market Segmentation Insights**

#### **Needle Biopsy Market Type Outlook**

#### **Needle Biopsy Market Application Outlook**

#### **Needle Biopsy Market Guidance Technique Outlook**

#### **Needle Biopsy Market End Use Outlook**

## Market Drivers

### Rising Geriatric Population

The increasing geriatric population in the US is a notable driver for the needle biopsy market. As individuals age, the risk of developing various health conditions, including cancer, escalates. The US Census Bureau projects that by 2030, approximately 20% of the population will be aged 65 and older. This demographic shift is likely to lead to a higher demand for diagnostic procedures, including needle biopsies, as older adults often require more frequent medical evaluations. Healthcare providers are adapting to this trend by incorporating needle biopsy techniques into routine diagnostic protocols, thereby propelling the growth of the needle biopsy market.

### Increasing Incidence of Cancer

The rising incidence of cancer in the US is a primary driver for the needle biopsy market. According to the National Cancer Institute, an estimated 1.9 million new cancer cases are expected to be diagnosed in 2025. This alarming trend necessitates effective diagnostic tools, with needle biopsies being a preferred method due to their minimally invasive nature. As healthcare providers seek to improve diagnostic accuracy and patient outcomes, the demand for needle biopsy procedures is likely to increase. Furthermore, advancements in imaging technologies enhance the precision of needle biopsies, making them more appealing to clinicians. Consequently, the needle biopsy market is poised for growth as it addresses the urgent need for timely and accurate cancer diagnosis.

### Enhanced Reimbursement Policies

Enhanced reimbursement policies for needle biopsy procedures are contributing to the growth of the needle biopsy market. Insurance companies and government programs are increasingly recognizing the value of these procedures in diagnosing various conditions, leading to improved reimbursement rates. This financial support encourages healthcare providers to adopt needle biopsy techniques more widely, as they can offer these services without significant financial burden. As reimbursement policies continue to evolve favorably, the needle biopsy market is likely to experience increased utilization, making these procedures more accessible to patients across the US.

### Growing Awareness of Early Diagnosis

There is a growing awareness among patients and healthcare providers regarding the importance of early diagnosis in improving treatment outcomes. This trend is particularly evident in the needle biopsy market, where early detection of malignancies can significantly influence survival rates. Educational campaigns and initiatives by health organizations are promoting the benefits of regular screenings and timely biopsies. As patients become more proactive about their health, the demand for needle biopsies is likely to rise. This shift in patient behavior is expected to drive growth in the needle biopsy market, as more individuals seek out these procedures for early cancer detection.

### Technological Innovations in Biopsy Techniques

Technological innovations are significantly influencing the needle biopsy market. The introduction of automated biopsy devices and advanced imaging techniques, such as ultrasound and MRI guidance, has improved the accuracy and efficiency of needle biopsies. These innovations not only enhance the precision of tissue sampling but also reduce the risk of complications, thereby increasing patient acceptance. The market is witnessing a shift towards more sophisticated devices that offer real-time imaging and feedback, which could potentially lead to better diagnostic outcomes. As healthcare facilities invest in cutting-edge technologies, the needle biopsy market is expected to expand, driven by the demand for enhanced diagnostic capabilities.

## Future Outlook

The [Needle Biopsy Market](https://www.marketresearchfuture.com/reports/needle-biopsy-market-3830) is projected to grow at 4.91% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures.

**New opportunities:**

- Development of advanced imaging-guided needle biopsy systems
- Expansion of telemedicine services for remote consultations
- Partnerships with diagnostic labs for integrated service offerings

By 2035, the needle biopsy market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Core Needle Biopsy (Largest) vs. Vacuum-Assisted Biopsy (Fastest-Growing)

In the US needle biopsy market, Core Needle Biopsy currently holds the largest market share among the segment values. This method has gained significant traction due to its balanced efficacy and minimal invasiveness, making it a preferred choice among practitioners. Fine Needle Aspiration Biopsy follows closely, while Vacuum-Assisted Biopsy, though not as prominent, is rapidly gaining ground.

The growth trends for these biopsy types reveal a dynamic landscape. Core Needle Biopsy remains a dominant player, bolstered by increasing awareness among healthcare professionals and patients about the advantages of early diagnosis. Meanwhile, the Vacuum-Assisted Biopsy segment is experiencing the fastest growth, driven by technological advancements and an increasing volume of diagnostic procedures that necessitate a reliable biopsy method.

Core Needle Biopsy (Dominant) vs. Vacuum-Assisted Biopsy (Emerging)

Core Needle Biopsy is characterized by its ability to provide larger tissue samples compared to Fine Needle Aspiration, supporting accurate diagnoses while ensuring patient comfort. This dominant segment benefits from extensive clinical application and positive surgeon feedback, solidifying its place in routine diagnostic procedures. Conversely, Vacuum-Assisted Biopsy, classified as an emerging value, is designed for more efficient sample collection, allowing multiple samples during a single insertion. This innovative method is gaining popularity due to its speed and precision, appealing to facilities aiming for enhanced efficiency and patient care. As both segments evolve, they are expected to co-exist, catering to diverse clinical needs in the US needle biopsy market.

### By Application: Oncology (Largest) vs. Gastroenterology (Fastest-Growing)

In the US needle biopsy market, Oncology dominates the application segment, accounting for a significant share due to the increasing prevalence of cancer and the rising demand for accurate diagnostic procedures. Cardiology and Pulmonology follow, reflecting a steady growth driven by advancements in minimally invasive techniques and the adoption of innovative technologies. Meanwhile, Gastroenterology is emerging rapidly, thanks to heightened awareness of gastrointestinal disorders and the effectiveness of needle biopsy in diagnosing such conditions.

Growth trends in the US needle biopsy market are propelled by technological innovations that improve precision and patient outcomes. The rise in the aging population and the incidence of chronic diseases contribute to the demand for efficient diagnostic tools in these applications. Additionally, funding for research and the development of refined biopsy techniques drive the growth, notably in the Gastroenterology sector, which is witnessing a surge in adoption as practitioners embrace these novel methodologies.

Oncology: Dominant vs. Gastroenterology: Emerging

Oncology represents a dominant force in the needle biopsy application segment, marked by a well-established framework for cancer diagnostics. The increasing rates of cancer detection and treatment options facilitate the sustained growth of this segment. On the other hand, Gastroenterology is marked as an emerging area within the US needle biopsy market, bolstered by growing awareness and effective diagnostic capabilities. As gastroenterologists adopt needle biopsies for conditions like liver biopsies and other gastrointestinal diseases, the segment showcases significant potential. The combination of technological advances and an emphasis on patient-centered care positions both Oncology and Gastroenterology as crucial players in enhancing the diagnostic landscape.

### By Guidance Technique: Ultrasound Guided (Largest) vs. CT Guided (Fastest-Growing)

The US needle biopsy market has demonstrated a diverse distribution across various guidance techniques, with Ultrasound Guided methods taking the lead in market share. This dominance can be attributed to their widespread acceptance in clinical practices due to their real-time imaging capabilities and cost-effectiveness, allowing for precise targeting in biopsies. Meanwhile, CT Guided techniques occupy a significant but smaller share, appealing primarily in cases where other methods may not provide adequate visualization.

In terms of growth trends, the CT Guided segment is rapidly emerging as the fastest-growing sector within this market. Drivers of this growth include advancements in imaging technology, improving accuracy, and rising demand for minimally invasive procedures. As healthcare providers continue investing in innovative tools, the shift towards CT Guided techniques is expected to accelerate, reflecting a broader trend towards enhanced diagnostic capabilities in the US needle biopsy market.

Ultrasound Guided (Dominant) vs. CT Guided (Emerging)

Ultrasound Guided techniques remain dominant in the US needle biopsy market, widely favored for their accessibility and real-time feedback that enhances procedural accuracy. They are particularly effective in soft tissue biopsies, where visualization is crucial. Conversely, CT Guided methods are emerging as a powerful alternative, particularly in more complex cases involving deep-seated lesions where ultrasound may fall short. This technique, while gaining momentum, is characterized by its ability to provide detailed cross-sectional images, facilitating better localization and sampling of tissues. As technology evolves, both segments are expected to refine their applications, yet Ultrasound Guided biopsy is likely to maintain its lead due to its established practice and broad range of applications.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the US needle biopsy market, hospitals hold the largest share, primarily due to the high volume of procedures performed in these institutions. They cater to a wide range of patients, thus facilitating the demand for various biopsy techniques. Conversely, diagnostic laboratories are gaining traction and witnessing rapid growth as they increasingly offer specialized testing services that cater to the needs of healthcare practitioners seeking accurate and timely results.

The growth trends in this segment are largely driven by technological advancements and increasing awareness of early cancer detection. As hospitals continue to invest in state-of-the-art medical devices, diagnostic laboratories are emerging as key players. They benefit from a shift towards more decentralized healthcare solutions, allowing for enhanced access to biopsy services, which further bolsters their growth potential in the US needle biopsy market.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals are recognized as the dominant players within the US needle biopsy market due to their established infrastructure and ability to provide comprehensive healthcare services. They offer a range of biopsy procedures, supported by experienced medical professionals and state-of-the-art technology. In contrast, diagnostic laboratories are classified as emerging players that focus on specialized testing, providing rapid and precise diagnostic solutions. Their growing importance is attributed to a rising demand for minimally invasive procedures, coupled with advancements in laboratory technology that enhance testing efficiency and accuracy. This dynamic demonstrates how each segment complements the other, with hospitals leading the market while diagnostic laboratories experience significant growth, adapting to the evolving landscape of healthcare.

## Competitive Benchmarking

The needle biopsy market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and technological advancements. Key players such as Becton Dickinson and Company (US), Hologic, Inc. (US), and Boston Scientific Corporation (US) are actively pursuing strategies that emphasize product development and market expansion. Becton Dickinson and Company (US) focuses on enhancing its product portfolio through continuous innovation, while Hologic, Inc. (US) is leveraging its expertise in women's health to introduce advanced needle biopsy solutions. Boston Scientific Corporation (US) appears to be concentrating on strategic acquisitions to bolster its market presence, thereby intensifying competition among these leading firms.The market structure is moderately fragmented, with several players vying for market share. Companies are adopting various business tactics, such as localizing manufacturing and optimizing supply chains, to enhance operational efficiency and reduce costs. This competitive structure allows for a diverse range of products and services, catering to the varying needs of healthcare providers and patients alike. The collective influence of these key players is significant, as they drive innovation and set industry standards, thereby shaping the overall market dynamics.

In September  Hologic, Inc. (US) announced the launch of its latest needle biopsy device, which integrates advanced imaging technology to improve accuracy and patient outcomes. This strategic move is likely to enhance Hologic's competitive edge by addressing the growing demand for precision in diagnostic procedures. The introduction of this device not only reinforces Hologic's commitment to innovation but also positions the company favorably against its competitors in the market.

In October  Boston Scientific Corporation (US) completed the acquisition of a leading needle biopsy technology firm, which is expected to expand its product offerings and enhance its market position. This acquisition reflects Boston Scientific's strategy to strengthen its portfolio and leverage synergies that could lead to improved operational efficiencies. The integration of this new technology may provide Boston Scientific with a unique advantage in delivering comprehensive solutions to healthcare providers.

In August  Becton Dickinson and Company (US) entered into a strategic partnership with a prominent healthcare technology firm to develop a next-generation needle biopsy system. This collaboration aims to combine Becton Dickinson's expertise in medical devices with cutting-edge digital health solutions. Such partnerships are indicative of a broader trend in the industry, where companies are increasingly seeking to integrate digital technologies into their product offerings to enhance patient care and streamline workflows.

As of November  the needle biopsy market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is becoming increasingly evident. Companies that prioritize innovation and adaptability are likely to emerge as leaders in this evolving market, as they respond to the dynamic needs of healthcare providers and patients.

## Recent News & Developments

The US Needle Biopsy Market has been increasingly dynamic in recent months, showcasing significant innovations and developments. In September 2023, Devicor Medical Products announced enhancements to its biopsy platform, improving precision in targeting lesions, which is expected to impact diagnostic accuracy positively. Meanwhile, Hologic expanded its portfolio with new biopsy systems tailored for breast cancer diagnostics, indicating a shift towards advanced technologies aimed at improving patient outcomes. Market demands are also evident with Boston Scientific's new partnerships to integrate advanced imaging techniques into their biopsy devices, thereby enhancing procedural efficiency.

Additionally, there have been notable movements in the corporate landscape, with Medtronic acquiring a niche player in the biopsy market in August 2023, which is aimed at broadening its product offerings. The overall market has seen consistent growth, with 2022 valuations reported at approximately USD 3 billion, and projections suggesting a compound annual growth rate of over 5% through 2028, underlining the potential for innovative biopsy solutions to address rising healthcare needs in the US. As companies like Ethicon and Cook Medical refine their strategies, competitive dynamics within the US Needle Biopsy Market continue to evolve robustly.

## Report Scope

| MARKET SIZE 2024 | 575.75(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 604.02(USD Million) |
| MARKET SIZE 2035 | 975.48(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.91% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Cook Medical LLC (US), Cardinal Health, Inc. (US), Terumo Corporation (JP), Fujifilm Holdings Corporation (JP), Olympus Corporation (JP) |
| Segments Covered | Type, Application, Guidance Technique, End Use |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance diagnostic accuracy in the needle biopsy market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive growth in the needle biopsy market, enhancing diagnostic accuracy and patient outcomes. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US needle biopsy market in 2024?**
A: The market valuation of the US needle biopsy market was $575.75 Million in 2024.

**Q: What is the projected market valuation for the US needle biopsy market by 2035?**
A: The projected market valuation for the US needle biopsy market is $975.48 Million by 2035.

**Q: What is the expected CAGR for the US needle biopsy market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US needle biopsy market during the forecast period 2025 - 2035 is 4.91%.

**Q: Which segment had the highest valuation in the US needle biopsy market in 2024?**
A: The Fine Needle Aspiration Biopsy segment had the highest valuation at $230.3 Million in 2024.

**Q: What are the key applications of needle biopsy in the US market?**
A: Key applications of needle biopsy in the US market include Oncology, Cardiology, Gastroenterology, and Pulmonology.

**Q: Which guidance technique generated the highest revenue in the US needle biopsy market in 2024?**
A: The Ultrasound Guided technique generated the highest revenue at $230.3 Million in 2024.

**Q: What was the market size for Core Needle Biopsy in 2024?**
A: The market size for Core Needle Biopsy was $215.5 Million in 2024.

**Q: Which end-use segment is expected to grow significantly in the US needle biopsy market?**
A: The Hospitals segment is expected to grow significantly, having reached $230.3 Million in 2024.

**Q: Who are the key players in the US needle biopsy market?**
A: Key players in the US needle biopsy market include Becton Dickinson and Company, Boston Scientific Corporation, and Hologic, Inc.

**Q: What is the projected growth trend for the US needle biopsy market by 2035?**
A: The US needle biopsy market is projected to grow steadily, reaching $975.48 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-needle-biopsy-market-19464*